[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641628":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":12,"centralContacts":27,"locations":33,"responsibleParty":45,"collaborators":49,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":12,"studyType":67,"phases":68,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":75,"whyStopped":12,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Assiut University","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard HRT protocol only. No additional injection","NO_INTERVENTION","arm will not recieve any injection",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Standard HRT protocol + Triptorelin 0.1mg subcutaneous injection, administered once 30-60 minutes af","EXPERIMENTAL","arm will recieve injection",[18],"Drug: GnRH agonist",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","GnRH agonist","women undergoing frozen ICSI cycles receiving progesterone + GnRH agonist for luteal phase support.",[14],[26],"triptofem0.1 amp",[28],{"name":29,"role":30,"phone":31,"phoneExt":12,"email":32},"Raafat Ahmed, master","CONTACT","+20 01029975352","raafatahmed4000@gmail.com",[34],{"facility":5,"status":12,"city":35,"state":36,"zip":12,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":12},"Asyut","Muslum","Egypt","EG",{"type":40,"coordinates":41},"Point",[42,43],31.18368,27.18096,{"lat":43,"lon":42},{"type":46,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"PRINCIPAL_INVESTIGATOR","Raafat Ahmed","residant doctor",[50],{"name":51,"class":6},"Woman's Health University Hospital, Egypt","100641628","phase-1-effect-of-gnrh-agonist-in-fet-100641628",false,"NCT07653282","Effect of GnRH Agonist in FET","Single Dose of Gonadotropin Releasing Hormone (GnRH)-Agonist as an Adjuvant Luteal Phase Support in Hormone Replacement Therapy (HRT) Frozen Embryo Transfer (FET) Cycles Prospective Comparative Study","gnrh agonist","Inclusion Criteria:\n\n* 1\\. Age 20-39 years 2. Undergoing HRT-FET cycle 3. ≥1 good quality embryo available , Gardner ≥3BB 4. Endometrial thickness ≥7mm on day of progesterone start 5. BMI 18-35 kg\u002Fm² 6. First or second FET cycle 7. Written informed consent\n\nExclusion Criteria:\n\n* 1\\. History of recurrent implantation failure ≥3 failed embryo transfers 2. Severe endometriosis Stage III-IV by ASRM 3. Uterine anomalies, submucous fibroid, or severe adenomyosis distorting cavity 4. History of recurrent pregnancy loss ≥2 consecutive 5. Contraindication or hypersensitivity to GnRH agonist 6. PGT-A cycles 7. Donor oocyte cycles",true,"FEMALE","20 Years","39 Years",{"count":65,"type":66},122,"ESTIMATED","INTERVENTIONAL",[69,70],"PHASE1","PHASE2","To evaluate the impact of single dose GnRH agonist administration as luteal phase support on pregnancy outcomes in frozen ICSI cycle",[73],"GnRH Agonist",[58],"NOT_YET_RECRUITING","2026-06-12",{"date":78,"type":79},"2026-06-17","ACTUAL",{"date":81,"type":66},"2026-08-01",{"date":83,"type":66},"2028-08-01",{"name":5,"class":6},1]